2023 IHN/MWPC Annual Meeting

August 30, 2023 to August 31, 2023

Subject matter experts that have direct experience implementing the following ideal practices are presenting:

  • Biosimilar contracting and identification of savings
  • DSCSA Preparedness
  • How to maximize reimbursement for hospitals/health systems
  • Optimizing the 340B Drug Discount Program in an Evolving Regulatory Landscape
  • Specialty pharmacy considerations, new pipeline approvals and site of care considerations in the ambulatory care landscape

Faculty will present information with a focus on how the attendee can use the information to implement it in their setting, including key takeaway points with each presentation. The audience will be engaged in polling and can ask questions to further their knowledge and confidence.

Target Audience

  • Pharmacists
  • Other Healthcare Professionals

Learning Objectives

 

08/30/2023 – The Final Countdown… to DSCSA – 1.0 Contact Hours

Carolyn Liptak, MBA, BSPharm

Pharmacy Executive Director

Vizient

At the conclusion of this activity, pharmacists should be able to:

  • Outline dispenser requirements for DSCSA.
  • Describe how to validate licensure of authorized trading partners.
  • Describe the role of GLNs for tracking and tracing.
  • Identify necessary steps for compliance.

08/31/202 - Against the wind… STOP running against the wind of biosimilars – 0.5 Contact Hours

Shannon Smallwood, PharmD, BCPS

Pharmacy Executive

Vizient

 

At the conclusion of this activity, pharmacists should be able to:

  • Outline biosimilar pipeline opportunities with upcoming product launches in the outpatient and retail settings.
  • Identify two best practices that can help improve current biosimilar uptake at your health system when transitioning to outpatient formulary management.
  • Describe one action item you can complete to help optimize adalimumab biosimilar usage.

 

08/31/202 - Take it to the Limit... Maximizing Reimbursement Payment Limits– 0.5 Contact Hours

Carolyn Liptak, MBA, BSPharm

Pharmacy Executive Director

Vizient

At the conclusion of this activity, pharmacists should be able to:

  • Discuss reimbursement from Centers for Medicare and Medicaid Services.
  • Identify ways to stay informed of new and changing NTAP drug payments that exist.
  • Explain proposed 2023 changes to Medicare reimbursement with operational changes required to implement them.
  • Implement a cross functional multidisciplinary approach to revenue cycle management.

08/31/2023 - Under Pressure…The Site of Care Challenge Causing More Pressure – 0.75 Contact Hours

Carina Dolan, PharmD, MSPharm, BCOP

AVP

Vizient

At the conclusion of this activity, pharmacists should be able to:

  • Discuss the impact of increasing ambulatory services for the health systems.
  • Describe the cost and spending implications of specialty medications on health-system pharmacy budgets.
  • Analyze growth in specialty based on medications in the FDA pipeline.

08/31/2023 - Upside down you’re turning me…let’s talk about 340B – 1.0 Contact Hours

Greg Medley, PharmD, MBA, 340B ACE, FASCP

Senior Director

Vizient

At the conclusion of this activity, pharmacists should be able to:

  • Explain 2022 and 2023 HRSA Program Integrity Results.
    • Provide tips for Mitigating HRSA Audit Risks.
  • Demonstrate how 340B savings are used to benefit patient care.
  • Explain the impact of the Consolidated Appropriation Act, 2023 and the Inflation Reduction Act on 340B practice.
  • Review Medicare/Medicaid 340B payment strategies.
  • Discuss contract pharmacy update.
  • Review strategies to mitigate impact of manufacturers’ restrictions.
  • Assess health equity and your 340B program operations.

Additional Information

Course summary
Available credit: 
  • 3.75 ACPE Pharmacist
  • 3.75 General CE - Attendance
Course opens: 
08/30/2023
Course expires: 
10/26/2023
Event starts: 
08/30/2023 - 11:00am CDT
Event ends: 
08/31/2023 - 12:30pm CDT
Convention Center
Cleveland, OH
United States

Faculty

Planning Committee

Alex Parish, PharmD, MBA
Pharmacy Executive
Vizient

Michelle Smith, PharmD, BCPS
Pharmacy Executive
Vizient

Shannon Smallwood, PharmD, BCPS
Pharmacy Executive
Vizient

Carolyn Liptak, MBA, BSPharm
Pharmacy Executive Director
Vizient

Carina Dolan, PharmD, MSPharm, BCOP
AVP
Vizient

Greg Medley, PharmD, MBA, 340B ACE, FASCP
Senior Director
Vizient

 

Faculty

Shannon Smallwood, PharmD, BCPS
Pharmacy Executive
Vizient

Carolyn Liptak, MBA, BSPharm
Pharmacy Executive Director
Vizient

Carina Dolan, PharmD, MSPharm, BCOP
AVP
Vizient

Greg Medley, PharmD, MBA, 340B ACE, FASCP
Senior Director 
Vizient 

 

 

Identification, Mitigation, and Disclosure of Relevant Financial Relationships

As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.

It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.

 

Disclosure of Financial Relationships:

Absence of Relevant Financial Relationships

Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.

No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.

 

Statement of Content Validity

Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

 

FDA off-label/unapproved usage

Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.

Usage Disclosure: “Off-label/unapproved drug uses or products are mentioned within this activity.

Evidence-based Content: Low/absence of evidence-based topics are mentioned within this activity

Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.

 

 

Joint Accreditation Statement

In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
 
 

Pharmacy

Vizient, Inc. designates this live activity for a maximum of 3.75 ACPE credit hours.

UAN JA0006103-0000-23-078-L04-P

 

Other Healthcare Professionals (General CE Credit)

Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation.  Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.

 

Available Credit

  • 3.75 ACPE Pharmacist
  • 3.75 General CE - Attendance
Please login or register to take this course.

 

Select the Obtain Credit button to access the activity evaluation and to claim CE Credit.